Profound Medical
Profound Medical
PROF
NASDAQ
7.00
USD
0.00%
About
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control.
TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia.
It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 8.4K |
| Three Month Average Volume | 197.5K |
| High Low | |
| Fifty-Two Week High | 11.13373 USD |
| Fifty-Two Week Low | 6.64545 USD |
| Fifty-Two Week High Date | 20 Nov 2023 |
| Fifty-Two Week Low Date | 10 Jan 2024 |
| Price and Volume | |
| Current Price | 8.60081 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -13.66% |
| Thirteen Week Relative Price Change | 17.78% |
| Twenty-Six Week Relative Price Change | -6.40% |
| Fifty-Two Week Relative Price Change | -10.77% |
| Year-to-Date Relative Price Change | -0.04% |
| Price Change | |
| One Day Price Change | -1.67% |
| Thirteen Week Price Change | 23.48% |
| Twenty-Six Week Price Change | 1.39% |
| Five Day Price Change | 1.15% |
| Fifty-Two Week Price Change | 2.66% |
| Year-to-Date Price Change | 11.35% |
| Month-to-Date Price Change | -15.63% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.3697 USD |
| Book Value Per Share (Most Recent Quarter) | 1.50466 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.34818 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.49032 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.21141 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.31905 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.32382 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -69585.83474 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -69585.83474 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.26614 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.14222 USD |
| Normalized (Last Fiscal Year) | -1.26614 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.26614 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.14222 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.26614 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.14222 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.15151 USD |
| Cash Per Share (Most Recent Quarter) | 1.30679 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.21535 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.08541 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.93706 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -333 |
| Cash Flow Revenue (Trailing Twelve Months) | -289 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -352.07% |
| Pretax Margin (Last Fiscal Year) | -398.62% |
| Pretax Margin (5 Year) | -385.73% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 60.87% |
| Gross Margin (Trailing Twelve Months) | 61.24% |
| Gross Margin (5 Year) | 50.32% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -397.50% |
| Operating Margin (Trailing Twelve Months) | -389.05% |
| Operating Margin (5 Year) | -387.20% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -396.85% |
| Net Profit Margin (Trailing Twelve Months) | -350.14% |
| Net Profit Margin (5 Year) | -387.15% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -4.19% |
| Tangible Book Value (5 Year) | 16.86% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 39.39% |
| Revenue Growth (3 Year) | 29.09% |
| Revenue Change (Trailing Twelve Months) | 16.67% |
| Revenue Per Share Growth | 11.19% |
| Revenue Growth (5 Year) | -0.48% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -1.96% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 18.53% |
| EPS Change (Trailing Twelve Months) | 10.91% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 7 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -37,001,770 |
| Net Debt (Last Fiscal Year) | -24,650,760 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 31 |
| Price to Sales (Trailing Twelve Months) | 28 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 6 |
| Price to Book (Most Recent Quarter) | 6 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 18 |
| Long Term Debt to Equity (Most Recent Quarter) | 11 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 5 |
| Quick Ratio (Most Recent Quarter) | 7 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -30,080,880 |
| Free Cash Flow (Trailing Twelve Months) | -30,763,530 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 25 |
| Total Debt to Equity (Most Recent Quarter) | 17 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -52.74% |
| Return on Assets (Trailing Twelve Months) | -51.65% |
| Return on Assets (5 Year) | -38.41% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -68.69% |
| Return on Equity (Trailing Twelve Months) | -66.00% |
| Return on Equity (5 Year) | -46.27% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -58.43% |
| Return on Investment (Trailing Twelve Months) | -61.16% |
| Return on Investment (5 Year) | -41.95% |